BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30799789)

  • 1. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
    Cimadamore A; Scarpelli M; Santoni M; Massari F; Tartari F; Cerqueti R; Lopez-Beltran A; Cheng L; Montironi R
    Curr Drug Metab; 2019; 20(4):305-312. PubMed ID: 30799789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers.
    Merae Alshahrani M
    Saudi J Biol Sci; 2022 Apr; 29(4):2072-2084. PubMed ID: 35531253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.
    Montironi R; Santoni M; Lopez-Beltran A; Cheng L; Moch H; Scarpelli M
    Curr Drug Targets; 2015; 16(2):96-102. PubMed ID: 25469883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
    González Del Alba A; Arranz JÁ; Puente J; Méndez-Vidal MJ; Gallardo E; Grande E; Pérez-Valderrama B; González-Billalabeitia E; Lázaro-Quintela M; Pinto Á; Lainez N; Piulats JM; Esteban E; Maroto Rey JP; García JA; Suárez C
    Crit Rev Oncol Hematol; 2017 May; 113():171-190. PubMed ID: 28427506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer.
    Cimadamore A; Aurilio G; Nolé F; Massari F; Scarpelli M; Santoni M; Lopez-Beltran A; Cheng L; Montironi R
    Cells; 2020 Jun; 9(6):. PubMed ID: 32575429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of multidrug resistance in tumors of the genitourinary tract.
    Theyer G; Hamilton G
    Urology; 1994 Dec; 44(6):942-50. PubMed ID: 7985331
    [No Abstract]   [Full Text] [Related]  

  • 7. Biennial report on genitourinary cancers.
    Fizazi K
    Eur J Cancer; 2016 Oct; 66():125-30. PubMed ID: 27569040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of advanced genitourinary tumors.
    Pietrantonio F; Biondani P; Verzoni E; Procopio G
    Tumori; 2012; 98(2):264-6. PubMed ID: 22677995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving Role of Genomics in Genitourinary Neoplasms.
    Devitt ME; Dreicer R
    Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Emerging Biomarkers in Genitourinary Tumors.
    Montironi R; Lopez-Beltran A; Cheng L
    Curr Drug Metab; 2017; 18(8):690-691. PubMed ID: 29113591
    [No Abstract]   [Full Text] [Related]  

  • 11. Genitourinary cancer.
    Hudes GR; Ozols RF; Schilder RJ
    Cancer Chemother Biol Response Modif; 1991; 12():509-48. PubMed ID: 1718377
    [No Abstract]   [Full Text] [Related]  

  • 12. Ciprofloxacin and Levofloxacin as Potential Drugs in Genitourinary Cancer Treatment-The Effect of Dose-Response on 2D and 3D Cell Cultures.
    Kloskowski T; Szeliski K; Fekner Z; Rasmus M; Dąbrowski P; Wolska A; Siedlecka N; Adamowicz J; Drewa T; Pokrywczyńska M
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present and future of personalized medicine in adult genitourinary tumors.
    Ciccarese C; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Conti A; Tortora G; Cascinu S; Montironi R
    Future Oncol; 2015; 11(9):1381-8. PubMed ID: 25952784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of circulating tumor cell detection in genitourinary cancer.
    Small AC; Gong Y; Oh WK; Hall SJ; van Rijn CJ; Galsky MD
    J Urol; 2012 Jul; 188(1):21-6. PubMed ID: 22578722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors.
    Carrozza F; Santoni M; Piva F; Cheng L; Lopez-Beltran A; Scarpelli M; Montironi R; Battelli N; Tamberi S
    Crit Rev Oncol Hematol; 2018 Nov; 131():1-6. PubMed ID: 30293699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies.
    Marciscano AE; Madan RA
    Curr Treat Options Oncol; 2018 Mar; 19(3):16. PubMed ID: 29520448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inside the 2015 ASCO Genitourinary Cancers Symposium.
    Santoni M; Massari F; Iacovelli R; Ciccarese C; Verri E; Burattini L; Montironi R; Nolè F; Tortora G; Cascinu S
    Future Oncol; 2015; 11(13):1859-62. PubMed ID: 26161923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The International Society of Urological Pathology Consultation on Molecular Pathology of Urogenital Cancer.
    van der Kwast TH; Egevad L; Kristiansen G; Grignon DJ
    Am J Surg Pathol; 2020 Jul; 44(7):859-861. PubMed ID: 32341239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
    Mann SA; Lopez-Beltran A; Massari F; Pili R; Fiorentino M; Koch MO; Kaimakliotis HZ; Wang L; Scarpelli M; Ciccarese C; Moch H; Montironi R; Cheng L
    Curr Drug Metab; 2017 Oct; 18(8):700-711. PubMed ID: 28524003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.